mDETECT featured in the National Post

mDETECT is among the four companies selected for BioCreate, the program funded by Ontario Genomics, a non-profit organization funded by the Government of Ontario and FedDev Ontario. mDetect has developed a blood test that detects six common cancers and provides doctors with information about how well a patient has responded to treatment.

mDETECT is an OBIO® member, an alumnus of our WiHI program, and presented at the OBIO® Investment Summit.

Previous
Previous

ProteinQure announces a breakthrough therapeutic in the fight against Triple-Negative Breast Cancer

Next
Next

Conavi and Titan Medical merge to help ignite widespread adoption of next-generation Novasight Hybrid intravascular imaging platform